Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28281173
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Neurotherapeutics
2017 ; 14
(2
): 284-297
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Glioma Subclassifications and Their Clinical Significance
#MMPMID28281173
Chen R
; Smith-Cohn M
; Cohen AL
; Colman H
Neurotherapeutics
2017[Apr]; 14
(2
): 284-297
PMID28281173
show ga
The impact of targeted therapies in glioma has been modest. All the therapies
that have demonstrated a significant survival benefit for gliomas in Phase III
trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine,
lomustine, vincristine]), and tumor-treating fields, are based on nonspecific
targeting of proliferating cells. Recent advances in the molecular understanding
of gliomas suggest some potential reasons for the failure of more targeted
therapies in gliomas. Specifically, the histologic-based glioma classification is
composed of multiple different molecular subtypes with distinct biology, natural
history, and prognosis. As a result of these insights, the diagnosis and
classification of gliomas have recently been updated by the World Health
Organization. However, these changes and other novel observations regarding
glioma biomarkers and subtypes highlight several clinical challenges. First, the
field is faced with the difficulty of reinterpreting the results of prior studies
and retrospective data using the new classifications to clarify prognostic
assessments and treatment recommendations for patients. Second, the new
classifications and insights require rethinking the design and stratification of
future clinical trials. Last, these observations provide the essential framework
for the development and testing of new specific targeted therapies for particular
glioma subtypes. This review aims to summarize the current literature regarding
glioma subclassifications and their clinical relevance in this evolving field.
free
free
free
